Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: A secondary analysis of clinical trial data from children with polyarticular-course juvenile idiopathic arthritis

Arthritis and Rheumatism

Volumn 60, Issue 12, 2009, Pages 3776-3783

  Ringold, Sarah ^a   Chon, Yun ^b   Singer, Nora G ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; METHOTREXATE; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; CHILD; DISEASE ACTIVITY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SECONDARY ANALYSIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; FEMALE; HEALTH STATUS; HUMANS; MALE; PEDIATRICS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RHEUMATOLOGY; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 73249126825     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24983     Document Type: Article

References (31)

1. Denardo BA, Tucker LB, Miller LC, Szer IS, Schaller JG. Demography of a regional pediatric rheumatology patient population: Affiliated Children's Arthritis Centers of New England. J Rheumatol 1994;21:1553-61.
2. Oen KG, Cheang M. Epidemiology of chronic arthritis in childhood. Semin Arthritis Rheum 1996;26:575-91.
3. Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol 1996; 23:1981-7.
4. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002;29:1989-99.
5. Zak M, Pedersen FK. Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford) 2000;39: 198-204.
6. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Reed M, et al. Early predictors of longterm outcome in patients with juvenile rheumatoid arthritis: subset-specific correlations. J Rheumatol 2003;30:585-93.
7. Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005;52:3554-62.
8. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
9. Brunner HI, Lovell DJ, Finck BK, Giannini EH. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 2002;29:1058-64.
10. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
11. Van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
12. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
13. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42: 244-57.
14. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis [review]. Clin Exp Rheumatol 2005;23 Suppl 39:S100-8.
15. Enbrel (etanercept) prescribing information. Thousand Oaks (CA): Immunex Corporation; 2009.
16. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Current proposed revision of the JRA criteria. Arthritis Rheum 1977;20 Suppl 2:195-9.
17. Lovell DJ, Giannini EH, Whitmore JB, Soffes L, Finck BK. Safety and efficacy of tumor necrosis factor receptor p75 Fc fusion protein (TNFR:Fc; Enbrel™) in polyarticular course juvenile rheumatoid arthritis [abstract]. Arthritis Rheum 1998;41 Suppl: S130.
18. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
19. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al, and the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
20. Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. QJM 1968;37:393-406.
21. Fransen J, Radovits B, Borm G, van Riel PL. The Disease Activity Score (DAS) with extended joint counts in rheumatoid arthritis: update and validation of the original DAS formula [abstract]. Arthritis Rheum 2007;56 Suppl:S709.
22. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59: 762-84.
23. Van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
24. Makinen H, Hannonen P, Sokka T. Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin Exp Rheumatol 2006; 24 Suppl 43:S22-8.
25. Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther 2005;85: 257-68.
26. Van Riel PL, van Gestel AM, van de Putte LB. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br J Rheumatol 1996;35 Suppl 2:4-7.
27. Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves [review]. Acta Paediatr 2007;96:644-7.
28. Brunner HI, Klein-Gitelman MS, Miller MJ, Barron A, Baldwin N, Trombley M, et al. Minimal clinically important differences of the childhood health assessment questionnaire. J Rheumatol 2005;32:150-61.
29. Lurati A, Pontikaki I, Teruzzi B, Desiati F, Gerloni V, Gattinara M, et al. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor α agents. Arthritis Rheum 2006;54:1602-7.
30. Bombardier C, Tugwell P. A methodological framework to develop and select indices for clinical trials: statistical and judgmental approaches. J Rheumatol 1982;9:753-7.
31. Palermo TM, Zebracki K, Cox S, Newman AJ, Singer NG. Juvenile idiopathic arthritis: parent-child discrepancy on reports of pain and disability. J Rheumatol 2004;31:1840-6.